BD intensifies syringe output to meet U.S. demand amid China quality concerns

BD intensifies syringe output to meet U.S. demand amid China quality concerns

BD’s North Canaan plant has increased its output of syringes by more than 40% to meet the needs of U.S. healthcare customers after the FDA launched an ongoing investigation into quality issues with plastic syringes made in China.

Provided

NORTH CANAAN — Becton, Dickinson and Company (BD) has ramped up its production of syringes at its North Canaan plant in response to quality issues with plastic syringes imported from China which were uncovered late last year by the U.S. Food and Drug Administration (FDA).

BD, a leading global medical technology company and Northwest Connecticut’s largest employer, responded to the FDA’s recommendation that consumers, healthcare providers and healthcare facilities transition away from plastic syringes made in China by increasing its domestic manufacturing of syringes at the company’s Connecticut and Nebraska facilities.

Since January, BD’s 385,000-square-foot North Canaan plant has increased its output of syringes “by over 40% to meet the needs of U.S. healthcare customers,” according to Fallon McLoughlin, director of public relations and corporate communications for the Franklin Lakes, N.J.-based company.

“BD has achieved this increase by driving operational efficiencies and relocating some production lines from other BD plants,” said McLoughin.

“We’ve added over 100 full-time associates in the last year, and currently have more than 500 full-time associates and nearly 50 contingent associates,” she said of the North Canaan site, which began its operations in 1961 with eight employees at a 25,000-square-foot facility.

BD draws its employees from throughout Northwest Connecticut and neighboring New York.

McLaughlin noted that its Connecticut plant primarily manufactures small-size syringes, and syringe and needle combination products that are “critical to the delivery of healthcare.”

Operations take place around the clock, producing more than 2 billion medical devices each year that are sold in every region worldwide.

Responding to consumer needs

In March, Eric Borin, president of BD Medication Delivery Solutions, announced a statement saying: “BD has the capacity to support additional syringe demand and is further increasing U.S. production to help ensure continuity of patient care.”

Since the initial FDA safety communication in November 2023, he noted, “BD has increased domestic manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer needs. Ensuring the safety and quality of our products is the top priority at BD.”

Borin further noted at the time that “The latest FDA safety communication does not include any BD syringes. Over our more than 125-year history, we have served the health care system’s need for essential high quality medical products, including manufacturing 2 billion additional syringes and needles to support the global pandemic response to COVID-19.”

Syringe manufacturers in China cited

In late November 2023, the FDA announced its probe into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China “that are used for injecting fluids into or withdrawing fluids from, the body,” according to the health regulator.

On March 14, the FDA issued an update on warning letters sent to three entities: Jiangsu Shenli Medical Production Co. Ltd, Medline Industries, LP and Sol-Millennium Medical Inc., describing violations related to the “sale and distribution of unauthorized plastic syringes that had not been cleared or approved by the FDA,” according to a new release.

“In addition, we are actively evaluating quality issues and performance testing failures with plastic syringes made by Jiangsu Caina Medical Co Ltd., a China-based manufacturer sited in the warning letter issued to Medline Industries, LP. The FDA will take additional steps as appropriate,” the FDA stated.

In its August 16 update, the FDA continued to recommend that healthcare providers “use syringes not manufactured in China, if possible.

“At this time, glass syringes, pre-filled syringes or syringes used for topical purposes are not included. If you only have syringes manufactured in China, then continue to use them as needed until you are able to use alternative syringes and closely monitor for leaks, breakage and other problems,” the FDA announced.

In March, BD was named to Fortune’s 2024 list of America’s Most Innovative Companies, and in September, the company announced that it had been named to TIME’s 2024 list of the World’s Best Companies based on employee feedback.

BD’s operations in North Canaan have also been recognized by the U.S. Environmental Protection Agency for achieving the Energy Star Challenge for Industry for energy reduction. The site is a landfill-free site where waste is reduced, recycled or converted into energy.

Latest News

Voters approve wakesurfing ban

The July 31 referendum in Kent, Warren and Washington banned wakesurfing on Lake Waramaug.

Photo by Alec Linden

The sport of wakesurfing is now banned on lake Waramaug as the result of a decisive tri-town vote held on Thursday, July 31.

Voters in Kent, Warren and Washington, the three towns that border Lake Waramaug, approved the ordinance with 1452 residents ultimately voting in favor of banning the sport against 421 opposed to it.

Keep ReadingShow less
2025 Jubilee Luncheon
   We look forward to seeing you!

Ruth Franklin discusses ‘The Many Lives of Anne Frank’ at Beth David

Ruth Franklin and Ileene Smith in conversation at Congregation Beth David in Amenia.

Natalia Zukerman

Congregation Beth David in Amenia hosted a conversation on the enduring legacy of Anne Frank, one of the 20th century’s most iconic figures. Ruth Franklin, award-winning biographer and critic, shared insights from her highly acclaimed book “The Many Lives of Anne Frank” with thought-provoking questions from Ileene Smith, Editorial Director of the Jewish Lives series. This event, held on July 23 — the date Anne Frank would have turned 96 — invited the large audience to reconsider Anne Frank not just as the young writer of a world-famous diary, but as a cultural symbol shaped by decades of representation and misrepresentation.

Franklin and Smith dove right in; Franklin reading a passage from the book that exemplified her approach to Anne’s life. She described her work as both a biography of Anne Frank and a cultural history of the diary itself, a document that has resonated across the world.

Keep ReadingShow less
Prokofiev, piano and perfection: Yuja Wang at Tanglewood

Yuja Wang performs with the TMCO and Andris Nelsons.

Hilary Scott

Sunday, July 20 was sunny and warm. Nic Mayorga, son of American concert pianist, the late Lincoln Mayorga, joined me at Tanglewood to hear Yuja Wang play Prokofiev’s Piano Concerto No. 2 in G minor, Op. 16. I first saw Wang on July 8, 2022, when she filled in for Jean-Yves Thibaudet on the opening night of Tanglewood’s summer season. She virtually blew the shed down with her powerful and dynamic playing of Liszt’s Piano Concerto No. 1.

Nic was my guest last season on July 13, when Wang wowed us with her delicate interpretation of Beethoven’s Piano Concerto No. 4. We made plans on the spot to return for her next date in Lenox.

Keep ReadingShow less